晚期膀胱癌抗体药物偶联物治疗中的先进影像学
本综述阐述抗体药物偶联物(ADC)治疗晚期膀胱癌时影像学的核心作用,涵盖CT、多参数MRI与FDG-PET在疗效评估、复发检测和毒性识别中的应用,并指出疗效评估主要依赖RECIST 1.1,多参数MRI在评估膀胱病灶完全缓解方面受到越来越多关注。
要点
- ADC治疗晚期膀胱癌的疗效评估主要依据RECIST 1.1,多参数MRI评估膀胱病灶完全缓解受到关注。
- 影像学还用于检测ADC相关毒性,包括肺炎和胃肠道并发症。
- 放射科医生需了解ADC治疗与影像学的演变,以优化患者管理。
核心结论
- 影像学在ADC治疗中起关键作用,超越诊断与分期,延伸至疗效评估、复发检测和毒性评价。
- ADC耐药机制如抗原丢失和载荷耐药持续构成挑战,需要开发下一代ADC。
- 影像学与ADC治疗的整合需要多学科方法以改善结局。
研究设计与样本
- 综述,聚焦晚期膀胱癌ADC治疗中的先进影像学,涉及恩诺单抗维多汀和德曲妥珠单抗。
诊断标准与关键数值
- 疗效评估主要依赖实体瘤疗效评价标准(RECIST)1.1。
- 多参数MRI用于评估膀胱病灶完全缓解的兴趣日益增长。
临床应用与阅片要点
- CT、多参数MRI和FDG-PET广泛用于ADC治疗的疗效评估、复发检测和毒性评价。
- 影像学有助于识别ADC相关毒性,包括肺炎和胃肠道并发症。
- 放射科医生需了解这些不断演变的治疗与影像学范式以优化患者管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Antibody-drug conjugates (ADCs) have revolutionized the treatment landscape for advanced bladder cancer, particularly enfortumab vedotin and trastuzumab deruxtecan, which target Nectin-4 and human epidermal growth factor receptor 2 (HER 2), respectively. These ADCs have shown substantial efficacy, improving survival in patients who have progressed after chemotherapy and immunotherapy. Imaging plays a pivotal role in ADC-based therapy, extending beyond diagnosis and staging to assessing treatment response, detecting recurrence, and evaluating toxicity. Computed tomography (CT), multiparametric magnetic resonance imaging (MRI), and fluorodeoxyglucose positron emission tomography (FDG-PET) are widely used for these purposes. Despite the efficacy of ADCs, resistance mechanisms such as antigen loss and payload resistance continue to pose challenges, necessitating the development of next-generation ADCs. Response assessment largely relies on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, with growing interest in multiparametric MRI for evaluating complete response in bladder lesions. Additionally, imaging helps identify ADC-related toxicities, including pneumonitis and gastrointestinal complications. Radiologists must be aware of these evolving therapeutic and imaging paradigms to optimize patient management. The integration of imaging with ADC-based treatment requires a multidisciplinary approach to improve outcomes. This review highlights the critical role of imaging in ADC therapy and underscores the need for radiologists to adapt to these advancements in bladder cancer treatment.
引用
- Eid S, Al-Yousef AS, Kim KW, et al. State-of-the-Art Imaging in Antibody-Drug Conjugate Treatment for Advanced Bladder Cancer. Korean J Radiol. 2025. PMID: 41015860. doi:10.3348/kjr.2025.0416
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。